Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 22, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general corporate financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs. On November 18, 2005, fund movements at a price of $52.05 per ADR resulted in an increase in the notional allocation of Ordinary Share ADRs for Mr. R Greig.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification pursuant to Disclosure Rules 3.1.4R(1)(a).
Key Facts for Investor Verification
- The filing reports a transaction for Mr. R Greig involving an increase in notional GSK Ordinary Share ADRs.
- The transaction was triggered by fund movements on November 18, 2005, at a price of $52.05 per ADR.
- The notification was issued on November 22, 2005, by the Plan Administrators.
- No financial performance data is included in this specific report.